Asymmetry Capital Management as of March 31, 2017
Portfolio Holdings for Asymmetry Capital Management
Asymmetry Capital Management holds 27 positions in its portfolio as reported in the March 2017 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Ptc Therapeutics I (PTCT) | 8.5 | $6.1M | 620k | 9.84 | |
| Centene Corporation (CNC) | 7.8 | $5.6M | 79k | 71.26 | |
| Synergy Pharmaceuticals | 7.1 | $5.1M | 1.1M | 4.66 | |
| Jazz Pharmaceuticals (JAZZ) | 6.8 | $4.9M | 34k | 145.14 | |
| HMS Holdings | 6.7 | $4.8M | 238k | 20.33 | |
| Bio-Rad Laboratories (BIO) | 6.3 | $4.5M | 23k | 199.36 | |
| Amicus Therapeutics (FOLD) | 6.3 | $4.5M | 635k | 7.13 | |
| Eli Lilly & Co. (LLY) | 6.3 | $4.5M | 54k | 84.09 | |
| UnitedHealth (UNH) | 5.8 | $4.2M | 25k | 164.03 | |
| Glaskosmithkline Adr | 5.3 | $3.8M | 90k | 42.16 | |
| Quest Diagnostics Incorporated (DGX) | 5.1 | $3.7M | 37k | 98.19 | |
| Sarepta Therapeutics (SRPT) | 3.6 | $2.6M | 87k | 29.61 | |
| Nevro (NVRO) | 3.6 | $2.6M | 27k | 93.71 | |
| Inogen (INGN) | 3.5 | $2.5M | 32k | 77.55 | |
| Aerie Pharmaceuticals | 3.1 | $2.2M | 49k | 45.35 | |
| Incyte Corporation (INCY) | 2.4 | $1.7M | 13k | 133.63 | |
| Puma Biotechnology (PBYI) | 2.2 | $1.6M | 43k | 37.20 | |
| Ironwood Pharmaceuticals (IRWD) | 1.9 | $1.4M | 82k | 17.06 | |
| Biogen Idec (BIIB) | 1.2 | $840k | 3.1k | 273.35 | |
| Alder Biopharmaceuticals | 1.2 | $826k | 40k | 20.81 | |
| Syndax Pharmaceuticals (SNDX) | 1.1 | $824k | 60k | 13.71 | |
| Cardinal Health (CAH) | 1.1 | $819k | 10k | 81.50 | |
| Astrazeneca Adr (AZN) | 1.1 | $773k | 25k | 31.16 | |
| Acadia Healthcare (ACHC) | 0.7 | $519k | 12k | 43.56 | |
| Keryx Biopharmaceuticals | 0.6 | $421k | 68k | 6.16 | |
| Regenxbio Inc equity us cm (RGNX) | 0.3 | $239k | 12k | 19.28 | |
| Clovis Oncology | 0.3 | $204k | 3.2k | 63.75 |
